Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

FDA rejects Summit, Akeso's ivonescimab in narrow lung cancer setting

The FDA rejected a new cancer treatment from Summit Therapeutics and Akeso in a decision that analysts largely expected, but ultimately shouldn’t dim the prospects for a promising class of drugs. Regulators turned down ivonescimab ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Health & Medicine

More from Sunday 15 November →